Abdominal Key

Fig. 10.1 Relationship between prostate cancer volume and Gleason score (ERSPC-Rotterdam data). The columns show the number of cases (n) visualizing the percentage of Gleason score 6, 7, and 8–10…

. Since 2003, millions have joined the men’s health movement, raising in excess of AUD $730 million and funding over 1,000 projects in 21 countries focusing on prostate cancer, testicular…

Fig. 9.1 A schematic representation of true biological progression of the disease that can occur if initially low-grade cancer cells or histologically normal cells transform into higher-grade cancer cells However,…

Fig. 6.1 Definition of overdiagnosis (From Etzoioni [55]. Used with permission) Fig. 6.2 Association of different treatment strategies with life expectancy and risk of PCa progression. The downhill slope between…

Company/test name Molecular type Primary endpoints Prolaris – cell cycle progression Gene expression (RNA quantification) Risk of biochemical recurrence, metastasis, and disease-specific mortality Genome DX – Decipher biopsy Gene expression (RNA quantification)…

  Risk assessment methods: frequency, timing, and triggers Study PSA test (every) DRE (every) Confirmatory biopsy (months) Repeated biopsiesa (every) Optional MRI Triggers for biopsy and/or MRI University of Toronto…

Fig. 14.1 Low-risk prostate cancer DM Patients’ Backgrounds As previous studies demonstrated [14, 15], patients have personal characteristics that may impact on the treatment DM process. Demographic, psychosocial and clinical…

Fig. 11.1 Man on active surveillance for prostate cancer (Gleason 3 + 3) diagnosed in 2010 4 cores of a TRUS standard 12-core biopsy (4 mm maximum cancer core length). The mpMRI…